ClinicalTrials.gg
RecruitingNCT07406971Cap-SPGASUpdated Feb 17, 2026

Safety of Transmucosal Capsaicin Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke

A Phase 2 interventional study of Capsaicin Transmucosal Oral Film and Placebo Transmucosal Oral Film in Ischemic Stroke, sponsored by Instituto Mexicano del Seguro Social. Recruiting at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Instituto Mexicano del Seguro Social · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Sep 2025, registered Feb 2026).
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Ischemic Stroke with a site in Mexico — 9 open to participants now, 10 under way, 3 of them phase 3. Ischemic Stroke · Mexico.

Planned enrollment
11th of 13
46 · median 270
Started
2025
the only one that year
Phase 2
2 of 19
1 open now
Registered
19th of 19
by date

Among the 19 studies in Ischemic Stroke with a site in Mexico, this one is the 11th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 2, and was the 19th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

9 of the 19 studies in Ischemic Stroke with a site in Mexico are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Ischemic Stroke with a site in Mexico, or all of them as a file.
02

Study summary

This study will evaluate the safety and tolerability of a dissolvable oral film containing a very small dose of capsaicin (the compound that produces the "hot" sensation in chili peppers) in adults with acute ischemic stroke. The film is designed to stimulate nerves in the mouth that may activate the sphenopalatine ganglion, a structure involved in regulating blood flow to the brain. The main purpose of this study is to determine whether the capsaicin film can be given safely to patients with acute ischemic stroke when started within 24 hours of symptom onset.

Participants will be randomly assigned (like flipping a coin) to receive either the capsaicin oral film or a placebo film that looks and tastes similar but contains no capsaicin. Neither the participants nor the clinical team will know which film is given (double-blind). All participants will continue to receive standard medical care for acute ischemic stroke.

After administration of the study film, participants will be closely monitored for side effects and changes in vital signs (blood pressure, heart rate, respiratory rate, temperature, and oxygen saturation) at prespecified time points up to 72 hours. The primary outcome is the frequency of adverse events related to the study product within 72 hours after treatment begins. Participants will also be followed clinically up to 3 months as part of usual stroke care.

The results of this study will help determine whether this approach is safe and feasible, and whether further studies are warranted.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

Keywords

  • Acute ischemic stroke
  • Capsaicin
  • Sphenopalatine ganglion stimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 80 years.
  • National Institutes of Health Stroke Scale (NIHSS) score between 6 and 20 at screening.
  • Symptom onset within 24 hours prior to study intervention.
  • Pre-stroke modified Rankin Scale (mRS) score ≤1.
  • Provision of written by the participant or legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  • Intracranial hemorrhage on neuroimaging.
  • Severe impairment of consciousness judged by the investigator to preclude safe participation.
  • Persistent blood pressure >220/120 mmHg after initial medical management.
  • Severe systemic disease that, in the investigator's judgment, may interfere with study participation or safety.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Transmucosal Capsaicin

    Drug: Capsaicin Transmucosal Oral Film

  • Placebo comparator
    Placebo Oral Film

    Drug: Placebo Transmucosal Oral Film

Interventions

  • DrugCapsaicin Transmucosal Oral Film

    A dissolvable transmucosal oral film containing a low dose of capsaicin designed for local administration in the oral cavity. The formulation is intended to provide controlled mucosal exposure to capsaicin for investigational neuromodulatory stimulation of trigeminal-parasympathetic pathways potentially involved in cerebral blood flow regulation. The film is administered once under clinical supervision in addition to standard medical care for acute ischemic stroke.

  • DrugPlacebo Transmucosal Oral Film

    A dissolvable transmucosal oral film identical in appearance, texture, and administration method to the active study film but without capsaicin. The placebo film is administered once under clinical supervision in addition to standard medical care for acute ischemic stroke to maintain blinding.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events Within 72 Hours After Administration

    The primary outcome is the proportion of participants experiencing any adverse event within 72 hours after administration of the study oral film. Adverse events include any unfavorable clinical sign, symptom, or change in vital signs temporally associated with study treatment, regardless of causality. Vital signs (blood pressure, heart rate, respiratory rate, temperature, and oxygen saturation) are recorded at predefined time points during the first 72 hours.

    Time frame: 72 hours after study intervention administration

Secondary outcomes

  1. Change in Systolic Blood Pressure Over 72 Hours

    Change in systolic blood pressure (mmHg) from baseline (pre-dose) to each prespecified post-dose assessment time point through 72 hours. Values will be summarized by treatment group.

    Time frame: Baseline (pre-dose) through 72 hours post-dose

  2. Change in Heart Rate Over 72 Hours

    Change in heart rate (beats per minute) from baseline (pre-dose) to each prespecified post-dose assessment time point through 72 hours. Values will be summarized by treatment group.

    Time frame: Baseline (pre-dose) through 72 hours post-dose

  3. Treatment Tolerability Within 72 Hours

    Proportion of participants who complete the assigned study oral film administration without discontinuation due to intolerance, and incidence of local tolerability symptoms (e.g., oral burning/irritation, excessive salivation, cough) within 72 hours after administration.

    Time frame: Up to 72 hours post-dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Marquez-Romero JM, Huerta-Franco MR, Vargas-Luna M, Madrigal-Gutierrez CA, Esparza-Hernandez JM, Velazquez-Barcena MG. Dose Escalation and Safety of Capsaicin for Cerebral Perfusion Augmentation: A Pilot Study. Stroke. 2021 Jul;52(7):2203-2209. doi: 10.1161/STROKEAHA.120.032773. Epub 2021 May 10. PubMed 33966493 ↗
  • Marquez-Romero JM, Garcia-Perales C, Garcia-Arellano M, Ortiz MS, Perez-Malagon CD, Huerta-Franco MR, Vargas-Luna FM. Capsaicin for Cerebral Perfusion Augmentation: A Randomized Open-Label Trial. Stroke. 2024 Apr;55(4):e112-e114. doi: 10.1161/STROKEAHA.123.046045. Epub 2024 Mar 8. No abstract available. PubMed 38456262 ↗

Individual participant data

Plan to share: Yes — Individual participant data underlying the results reported in publications may be shared with qualified researchers upon reasonable request, subject to institutional approval, data use agreements, and applicable privacy regulations.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning after publication of the primary study results and continuing for up to 5 years thereafter.

Access criteria: Requests should include a methodologically sound proposal. Data sharing will require approval by the study investigators and execution of a data use agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 12 months after the start.

Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 12 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 12, 2026
StartActual
Sep 1, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Oct 31, 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07406971
Collaborators
Centenario Hospital Miguel Hidalgo
Responsible party
Juan Manuel Marquez Romero (Principal investigator, Instituto Mexicano del Seguro Social) — Principal investigator
First posted
Feb 12, 2026
Start date
Sep 1, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Juan M Marquez-Romero, MD, PhD
Contact
scint1st@gmail.com
+524499136423

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion